937
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway

ORCID Icon, , , , , , , , , , , ORCID Icon & show all
Pages 264-268 | Received 30 Apr 2022, Accepted 23 Aug 2022, Published online: 05 Sep 2022

References

  • Bell AM, Wagner JL, Barber KE, et al. Elbasvir/grazoprevir: a review of the latest agent in the fight against hepatitis C. Int J Hepatol. 2016;2016:3852126. https://www.hindawi.com/journals/ijh/2016/3852126/
  • Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. A randomized trial C-EDGE treatment naive trial of grazoprevir–elbasvir. Ann Intern Med. 2015;163(1):1–13. https://doi.org/10.7326/M15-0785.
  • Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection – 16 weeks vs 12 weeks. 66th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA 2015. https://www.natap.org/2015/AASLD/AASLD_47.htm
  • Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194. https://doi.org/10.1016/j.jhep.2016.09.001.
  • Recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. https://doi.org/10.1016/j.jhep.2018.03.026.
  • Recommendations on treatment of hepatitis C 2020. J Hepatol. 2020;73(5):1170–1218. https://doi.org/10.1016/j.jhep.2020.08.018.
  • Midgard H. Management of hepatitis C virus infection among people who inject drugs: Treatment uptake, reinfection and risk behaviours [PhD thesis]. University of Oslo; 2017. https://www.duo.uio.no/handle/10852/61510.
  • Ahmed H, Abushouk AI, Menshawy A, et al. Meta-analysis of grazoprevir plus elbasvir for treatment of hepatitis C virus genotype 1 infection. Ann Hepatol. 2018;17(1):18–32. https://www.medigraphic.com/pdfs/hepato/ah-2018/ah181e.pdf
  • Knops E, Sierra S, Kalaghatgi P, et al. Epistatic interactions in NS5A of hepatitis C virus suggest drug resistance mechanisms. Genes (Basel). 2018;9(7):343. https://doi.org/10.3390/genes9070343.
  • Palladino C, Esteban-Cartelle B, Mate-Cano I, et al. Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain. Enferm Infecc Microbiol Clin (Engl Ed). 2018;36(5):262–267. https://doi.org/10.1016/j.eimc.2017.03.008.
  • WHO. Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. World Health Organization; 2016. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
  • Wisløff T, White R, Dalgard O, et al. Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies. J Viral Hepat. 2018;25(9):1066–1077. https://doi.org/10.1111/jvh.12904.
  • Toresen KH, Salte IM, Skrede S, et al. Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic. Scand J Gastroenterol. 2014;49(4):465–472. https://doi.org/10.3109/00365521.2013.863965.
  • Sølund C, Hallager S, Pedersen MS, DANHEP group, et al. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scand J Gastroenterol. 2018;53(7):849–856. https://doi.org/10.1080/00365521.2018.1467963.